دورية أكاديمية
أعرض في EDS

A higher platelet-to-lymphocyte ratio is prevalent in the presence of circulating tumor microemboli and is a potential prognostic factor for non-metastatic colon cancer.

التفاصيل البيبلوغرافية
العنوان: A higher platelet-to-lymphocyte ratio is prevalent in the presence of circulating tumor microemboli and is a potential prognostic factor for non-metastatic colon cancer.
المؤلفون: Abdallah EA; International Research Center, A.C. Camargo Cancer Center, 440 Taguá Street, Liberdade, 01508-010 São Paulo, SP, Brazil., Souza E Silva V; Department of Medical Oncology, A.C. Camargo Cancer Center, São Paulo, Brazil., Braun AC; International Research Center, A.C. Camargo Cancer Center, 440 Taguá Street, Liberdade, 01508-010 São Paulo, SP, Brazil., Gasparini VA; International Research Center, A.C. Camargo Cancer Center, 440 Taguá Street, Liberdade, 01508-010 São Paulo, SP, Brazil., Kupper BEC; International Research Center, A.C. Camargo Cancer Center, 440 Taguá Street, Liberdade, 01508-010 São Paulo, SP, Brazil., Tariki MS; Department of Medical Oncology, A.C. Camargo Cancer Center, São Paulo, Brazil., Tarazona JGR; International Research Center, A.C. Camargo Cancer Center, 440 Taguá Street, Liberdade, 01508-010 São Paulo, SP, Brazil., Takahashi RM; Department of Pelvic Surgery, A.C. Camargo Cancer Center, São Paulo, Brazil., Aguiar Júnior S; Department of Pelvic Surgery, A.C. Camargo Cancer Center, São Paulo, Brazil., Chinen LTD; International Research Center, A.C. Camargo Cancer Center, 440 Taguá Street, Liberdade, 01508-010 São Paulo, SP, Brazil. Electronic address: ludmilla.chinen@accamargo.org.br.
المصدر: Translational oncology [Transl Oncol] 2021 Jan; Vol. 14 (1), pp. 100932. Date of Electronic Publication: 2020 Nov 03.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Neoplasia Press Country of Publication: United States NLM ID: 101472619 Publication Model: Print-Electronic Cited Medium: Print ISSN: 1936-5233 (Print) Linking ISSN: 19365233 NLM ISO Abbreviation: Transl Oncol Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: [Ann Arbor, MI] : Neoplasia Press
مستخلص: Colorectal cancer is a common and often deadly cancer. Circulating tumor cells (CTCs) have been implicated as a potentially valuable prognosis factor. The detection of circulating tumor microemboli (CTM) and of simple blood component parameters that reflect inflammatory status, such as the platelet-to-lymphocyte ratio (PLR) and neutrophil-to-lymphocyte ratio (NLR), may provide information about tumor progression. The aim of this study was to explore the importance of CTCs, CTM, PLR, and NLR prospectively in non-metastatic colon cancer progression. CTCs were enriched using ISET Ⓡ (Isolation by SizE of Tumor cells) and identified by immunocytochemical exclusion of leukocytes. We evaluated CTCs and blood cell parameters in a cohort of 69 stage I-III colon cancer patients (52.2% men; median age, 61 years; age range, 19-87 years) at a baseline timepoint prior to resection surgery. The median of CTC levels at baseline was 20 cells/8 mL (0-94) and higher levels were associated with CTM presence (p = 0.02). CTM were found in 18 (26.1%) patients. Of 18 stage I patients, 33.3% had CTM and of 51 stages II or III patients, 13.7% had CTM (p = 0.08). Patients with a high PLR (>124) were mostly (75.6%) diagnosed with high-risk stages II/III cancer (stages I/low-risk II, 24.4%; p = 0.014). All 8 patients that had disease recurrence during follow-up had a high PLR (p = 0.02 vs. low PLR). NLR was not significantly associated with disease stage or recurrence. The present results indicate that CTCs and PLR analyses may be clinically useful for colon cancer management and risk stratification.
Competing Interests: Declaration of Competing Interest The authors have declared no conflict of interest.
(Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.)
References: Theranostics. 2013 Apr 23;3(6):377-94. (PMID: 23781285)
EMBO Mol Med. 2014 Nov 14;7(1):1-11. (PMID: 25398926)
Genes Dev. 2018 Oct 1;32(19-20):1267-1284. (PMID: 30275043)
Asian Pac J Cancer Prev. 2014;15(6):2647-50. (PMID: 24761878)
Mol Cell. 2014 Apr 24;54(2):281-8. (PMID: 24766892)
Surg Today. 2020 Oct;50(10):1272-1281. (PMID: 32346761)
Nat Rev Cancer. 2006 Jan;6(1):24-37. (PMID: 16397525)
Biomed J. 2020 Feb;43(1):18-23. (PMID: 32200952)
Oncotarget. 2016 Sep 20;7(38):62754-62766. (PMID: 27517159)
Clin Transl Gastroenterol. 2019 Jul;10(7):e00055. (PMID: 31246593)
BMC Res Notes. 2017 Jan 3;10(1):12. (PMID: 28057051)
Dis Colon Rectum. 2017 Oct;60(10):999-1017. (PMID: 28891842)
Folia Histochem Cytobiol. 2017;55(1):1-5. (PMID: 28509310)
PLoS One. 2014 Jun 26;9(6):e101119. (PMID: 24968121)
J Thorac Oncol. 2012 Feb;7(2):306-15. (PMID: 22173704)
Cells. 2019 Jul 13;8(7):. (PMID: 31337010)
Onco Targets Ther. 2014 Apr 17;7:619-25. (PMID: 24790460)
Nature. 2019 Feb;566(7745):553-557. (PMID: 30728496)
J Neuroimmune Pharmacol. 2006 Dec;1(4):421-7. (PMID: 18040814)
Ann Surg Oncol. 2010 Jun;17(6):1471-4. (PMID: 20180029)
Trends Immunol. 2019 Jul;40(7):556-559. (PMID: 31101536)
J Clin Oncol. 2009 Jul 1;27(19):3109-16. (PMID: 19451431)
Sci Rep. 2016 Apr 14;6:24517. (PMID: 27075165)
J Clin Lab Anal. 2020 Apr;34(4):e23132. (PMID: 31755593)
J Cancer. 2018 Aug 6;9(17):3093-3100. (PMID: 30210632)
BMC Cancer. 2018 Dec 3;18(1):1202. (PMID: 30509242)
CA Cancer J Clin. 2018 Nov;68(6):394-424. (PMID: 30207593)
Oncotarget. 2017 Sep 21;8(49):86287-86295. (PMID: 29156795)
Oncologist. 2019 Sep;24(9):e854-e863. (PMID: 30846515)
Cancer Metastasis Rev. 2019 Jun;38(1-2):297-305. (PMID: 31053984)
PLoS One. 2014 Oct 31;9(10):e111597. (PMID: 25360587)
Sci Rep. 2018 Jun 21;8(1):9453. (PMID: 29930287)
فهرسة مساهمة: Keywords: Circulating tumor cells; Circulating tumor microemboli; Colon adenocarcinoma; Liquid biopsy; Platelet-to-lymphocyte ratio
تواريخ الأحداث: Date Created: 20201106 Latest Revision: 20210110
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC7649529
DOI: 10.1016/j.tranon.2020.100932
PMID: 33157516
قاعدة البيانات: MEDLINE
الوصف
تدمد:1936-5233
DOI:10.1016/j.tranon.2020.100932